Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy
We would like to address several challenges that have arisen from the study by Morimoto et al. , which are specifically summarized below.
Missing data from the article by Morimoto et al. (1)
PCV duration before entry into the study
The anatomic types of macular edema (diffuse/subretinal fluid/cystic changes within neurosensory retina/mixed type) at presentation and at year 2
The proportions of the eyes with complete regression of polypoidal lesions and complete dry macula at year 2
The proportion of the eyes with recurrent exudative changes up to the end of the study
The anatomic lesions of the PCV (serosanguineous detachments of RPE and neurosensory retina, polypoidal lesions, abnormal branch vascular networks, vitrous hemorrhage, subretinal fibrosis, pigment epithelial hyperplasia, and atrophic degeneration) at baseline and at the end of the follow-up
The quantification of the...
KeywordsAflibercept Treat-and-extend regimen Polypoidal choroidal vasculopathy Central macular thickness Central choroidal thickness
Compliance with ethical standards
Conflict of interest
All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.
- 1.Morimoto M, Matsumoto H, Mimura K, Akiyama H (2017) Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol, https://doi.org/10.1007/s00417-017-3718-6 Published online: July 01, 2017
- 5.Gharbiya M, Cruciani F, Mariotti C, Grandinetti F, Marenco M, Cacace V (2015) Choroidal thickness changes after intravitreal antivascular endothelial growth factor therapy for age-related macular degeneration: ranibizumab versus aflibercept. J Ocul Pharmacol Ther 31(6):357–362CrossRefPubMedGoogle Scholar
- 8.Hikichi T (2017) Six-year outcomes of antivascular endothelial growth factor monotherapy for polypoidal choroidal vasculopathy. Br J Ophthalmol. https://doi.org/10.1136/bjophthalmol-2017-310448 Published on May 25, 2017